The words should help—not become another barrier.

Another molecular or clinical finding kept visible because it may affect interpretation.

The available sources do not contain an answer for that field or clinical area.

A gene involved in chromatin regulation. Disease-causing variants are associated with an autosomal dominant syndromic neurodevelopmental disorder.

The person’s defined usual function and context before a change or comparison window.

DNA together with associated proteins and chemical marks that help regulate genome organization and gene activity.

The 63 people whose information, shared by individuals and families, is currently represented in group-level summaries on this site.

A sequence that records what demand or condition was active during a change—such as illness, sleep loss, pain, medication, sensory demand, or task difficulty—then the observable event, time-matched measurement, action, and return toward baseline.

A deletion or duplication affecting a genomic interval that may include ASH1L and sometimes other genes.

A change not detected in tested parental samples, subject to identity, sample, and assay limits.

Attributing a new symptom, behavior, or functional change to an existing diagnosis without proportionate assessment of other explanations.

Known relatives are identified so they are not treated as independent recurrence events.

Direct caregiver or individual observation of function, timing, change, context, or recovery.

A clinical result described by a family before the original record is available.

A position on histone H3 that can carry methyl marks involved in chromatin regulation; ASH1L has H3K36 methyltransferase activity in experimental systems.

A disease mechanism in which one functional copy of a gene is not sufficient for typical function.

The available sources contain some information relevant to a defined field or clinical area.

A reported genetic change passed from a biological parent to their child.

A molecular consequence expected to reduce or disrupt normal gene product, subject to transcript, position, and variant-specific interpretation.

A sequence change that replaces one amino acid with another.

An exact molecular result is recorded in the information available to this project.

A cellular RNA-surveillance process that can reduce transcripts containing certain premature stop signals.

A direct report, laboratory result, imaging study, EEG, examination, or other primary clinical source.

At least one relevant original clinical or laboratory record is available for that person and clinical area.

The proportion of people with a defined genotype who meet a clearly defined phenotype under adequate ascertainment.

Documented permission, consent, or publication approval that determines whether information may be used or published.

Observable or measurable characteristics, functions, diagnoses, and clinical findings.

Video, photograph, audio, or other visible material that may support review when its context is clear and the person or family has agreed it may be used.

A molecular result whose stated reference and amino-acid position support comparison on a specified protein coordinate system.

A proposed explanation or testable research question kept separate from observations and measurements.

The catalytic protein region central to ASH1L histone-methyltransferase activity.

A working description for a demonstrated ability that is not expressed reliably across different body, brain, task, or environmental states.

The RNA reference sequence used to describe a genetic change and derive its cDNA and protein consequence.

Differences in which features appear, their degree, timing, or impact among people with a related genetic condition.

A laboratory classification used when current evidence is insufficient or conflicting.